IDYA

In the past six months, IDYA's stock has trended down by 6.61%, although it has trended up by 58.38% over the past year. On April 13, 2026, IDEAYA Biosciences and Servier announced positive topline results from their Phase 2/3 registrational trial of darovasertib in combination with crizotinib, leading to a surge in retail sentiment. On April 30, 2026, IDEAYA announced its intention to initiate a New Drug Application (NDA) submission for darovasertib, with the FDA's agreement to review under RTOR. On May 5, 2026, the company reported its first-quarter 2026 financial results, highlighting approximately $972.9 million in cash, cash equivalents, and marketable securities, with cash runway guidance into 2030. In the past three months, IDEAYA Biosciences insiders have bought more of the company's stock than they have sold, with one director buying 50,000 shares in March 2026.